| Application no. and date | 10164976.2 (espacenet) (Federated) (European Patent Register), 20050517 | | Patent/reg. no. and date | DK/EP 2228064, 20191211 | | Publication date | 20100915 | | Priority no. and date | GB 0411056, 20040518 | | EP pub. no. and date |
EP 2228064 20100915 | | Effective date | | | Applicant/owner | Novartis AG, Lichtstrasse 35
4056 Basel, CH | | Applicant ref. no. | BT/GP/160285 | | Inventor | Collingwood, Stephen Paul,
Novartis Horsham Research Centre Wimblehurst Road
Horsham,, Sussex RH12 5AB, GB | | Representative | Budde Schou A/S, Dronningens Tværgade 30, 1302 København K, DK | | Opponent | | | IPC Class | A61K 31/402 (2006.01) , A61K 31/4704 (2006.01) , A61P 11/00 (2006.01) | | Title | Farmaceutisk sammensætning, der indeholder glycopyrrolat og en beta2-adrenoceptoragonist | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | CA 2020 00024 | | Status | Ophævet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
